Donate

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer

Clinical Trials

Institution: Memorial Sloan Kettering, Fox Chase Cancer Center, Johns Hopkins Medical Center

Type: Multi-Center Trial

Purpose:

The purpose of this study is to find the best dose of the investigational drugs guadecitabine and mocetinostat to be given safely and effectively with pembrolizumab immunotherapy in patients with metastatic non-small cell lung cancer. Pembrolizumab works by blocking a molecule called PD-1 that shuts down the immune response. Blocking PD-1 can allow the immune system to detect and attack cancer cells. Guadecitabine and mocetinostat are “epigenetic therapies” that work on certain genes that may be turned on or off in cancer. Pembrolizumab is given intravenously (by vein). Guadecitabine is given by subcutaneous (under the skin) injection, and mocetinostat is taken orally (by mouth).

Dates: August 4, 2017 - July 31, 2020

Disease: Lung Cancer

Contact:

By center:

Memorial Sloan Kettering
Matthew Hellman, MD
[email protected]
646-888-4863

Fox Chase
Hossein Borghaei, MS, DO
[email protected]
888-369-2427 or 215-214-4297

Johns Hopkins
Jarushka Naidoo, MBBCh
[email protected]
410-955-8866

Page last updated: April 13, 2020

No upcoming events near you